Yokogawa introduces CellVoyager High-Content Analysis System CQ3000

Yokogawa Electric Corporation (TOKYO: 6841) today announced the introduction of the CQ3000, a high-content analysis system for capturing high-definition 3D microscopic images of live cell cultures. Expanding the company’s CellVoyager™ family of products, the CQ3000 will be launched commercially later in 2024.

The CQ3000 has been designed to capture 3D microscopic images of live cell cultures in high definition at high speed. When used together with Yokogawa’s CellPathfinder image analysis software, the CQ3000 can quantify and analyze intracellular organelles to assess cellular reactions and the effects of drug compounds. It enables highly efficient evaluation of cells in a wide range of applications, from basic research to drug discovery screening.

“The CQ3000 is an enhancement to the CellVoyager series lineup that will accelerate the development of new drugs and streamline basic research in cutting-edge biology and medicine. Through the provision of products and solutions that contribute to drug discovery research and the advancement of individualized medicine and regenerative medicine, Yokogawa’s aims to ensure well-being and quality of life for all.”

Hiroshi Nakao, Vice President and head of the Life Business Headquarters at Yokogawa Electric

About CQ3000

High-definition observation of living cells over long time periods

The CQ3000 enables the stable and precise observation of live cell cultures over long time periods thanks to Yokogawa's high-precision temperature control and dual spinning-disk with microlens that captures optical slice images (confocal images) with higher speed and better sensitivity, which minimizes damage to cells compared to other confocal systems on the market.

High speed screening

The CQ3000 can capture images of microplates at high speed thanks to enhancements to its stage control and auto-focus functions. When used in combination with optional dual camera and wide-field image capture feature, which uniformly captures the entire field of view, image capture time is reduced. This product enables the high-speed selection of promising chemical compounds from vast numbers of new drug candidates.

High image quality

By using Yokogawa’s proprietary water immersion lens mechanism, in addition to detailed observation at high magnification levels, it is also possible to capture bright images at low magnification levels. The use of an optional uniformizer achieves even illumination across the entire field of view, for the capture of vivid images.

To learn more about the CQ3000 please visit: https://www.yokogawa.com/solutions/products-and-services/life-science/high-content-analysis/high-content-analysis-system-cq3000/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Yokogawa Life Science. (2024, February 02). Yokogawa introduces CellVoyager High-Content Analysis System CQ3000. News-Medical. Retrieved on April 16, 2024 from https://www.news-medical.net/news/20240202/Yokogawa-introduces-CellVoyager-High-Content-Analysis-System-CQ3000.aspx.

  • MLA

    Yokogawa Life Science. "Yokogawa introduces CellVoyager High-Content Analysis System CQ3000". News-Medical. 16 April 2024. <https://www.news-medical.net/news/20240202/Yokogawa-introduces-CellVoyager-High-Content-Analysis-System-CQ3000.aspx>.

  • Chicago

    Yokogawa Life Science. "Yokogawa introduces CellVoyager High-Content Analysis System CQ3000". News-Medical. https://www.news-medical.net/news/20240202/Yokogawa-introduces-CellVoyager-High-Content-Analysis-System-CQ3000.aspx. (accessed April 16, 2024).

  • Harvard

    Yokogawa Life Science. 2024. Yokogawa introduces CellVoyager High-Content Analysis System CQ3000. News-Medical, viewed 16 April 2024, https://www.news-medical.net/news/20240202/Yokogawa-introduces-CellVoyager-High-Content-Analysis-System-CQ3000.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.